Regeneron Pharmaceuticals Inc (REGN) Buy,…

Home

Daily Stock Opinions and Ratings

Regeneron Pharmaceuticals Inc (REGN)

781.49

-11.77 (1.48%)

as of Sep 11, 2026, 8:00:00 pm Market Open.

67 watching

Investor Insights

Sep 11, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Regeneron Pharmaceuticals Inc has recently faced criticism following disappointing results from a cancer drug trial, which had raised expectations for success. The negative news has led to a significant drop in its stock price, falling 10% in a single day, generating concerns over potential future downgrades from analysts. Despite this setback, it is noteworthy that the stock has seen a remarkable rise of 53% over the last six months, indicating that it had been on a positive trajectory prior to this incident. This dual narrative of acute short-term trouble contrasted with longer-term gains paints a complex picture for investors, asserting the need for careful evaluation of the stock's potential moving forward.

Consensus

Mixed

Valuation

Overvalued

Similar

AMGN

BUY

It trades at 13x earnings. Their pipeline is really good but was under pressure given drug pricing issues. This has outperformed the market this year. They have a strong pipeline of drugs and trades at an attractive valuation.

Wealthica Track your Stocks in your Watch List

BUY

Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron.

HOLD

Large cap biotech. Its two franchises are dominant: macular degeneration and atopic dermatitis. One of the best at R&D. Proven ability to execute. One of the better growth profiles for next 3-5 years. Bit of volatility around reimbursement. Decent valuation. No dividend.

COMMENT

They report Friday. Sells at 11x earnings. They have drugs for asthma and other illnesses.

BUY

On Monday, they host an investors' event to showcase their work in RNA-based therapies and gene editing. Though it's a biotech, REGN is profitable and trades at a low PE. It trades on earnings and not future sales. If they tell a great story next week, he expects this stock to break out to an all-time high.

BUY

Not only REGN, but all healthcare stocks, like Bristol-Myers and Merck, have been under pressure. REGN is a great stock and worth holding long-term.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 23/20, Up 9.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with REGN has triggered its stop at $565. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment gain of 15%.

BUY

It hit a new 52-week high today, based on it successful Covid treatment that gets patients out of the hospital a lot faster.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 24/20, Up 22.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with REGN has achieved its $630 objective. To be disciplined, we recommend covering 50% of the position and trailing up the stop (from $425) to $565.

COMMENT

They developed a Covid treatment drug, but Washington has been unkind to them and made it inaccessible to the public. A great company, but it can't work for free.

HOLD

It confuses him. They produce great drugs and are run by a fine CEO, but they aren't making a lot of money on their Covid cocktail. The stock has been struggling, but he would not sell.

BUY ON WEAKNESS

Buy it under $500. It hasn't been in the news lately. They have a great Covid drug, but aren't making enough of it.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly REGN’s COV2 antibody treatment used by the US President during his treatment has been granted Emergency Use Authorization by the FDA. Even though vaccine alternatives are coming, this will provide treatment options for those infected and will help reduce hospitalizations. We would buy this with a $425 stop-loss looking to achieve $630 – 21% upside. Yield 0% (Analysts’ price target is $628.52)

PAST TOP PICK

(A Top Pick Jul 17/19, Up 95%) They've developed an antibody for Covid. Great company that he's been adding to. Fine valuation. They have a fine franchise in a severe atopic dermatitis drug. They're also developing an asthma drug that looks promising.

BUY

Just announced that their new drug cocktail can treat Covid immediately upon testing positive. The stock actually went down today, but he's been recommending this for a while.

Showing 16 to 30 of 35 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Capital Wealth Planning

Greg Newman

Scotia Wealth Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Regeneron Pharmaceuticals Inc (REGN)